Fig. 5: Vulnerability of GSPT1-KO U87 cells to apoptosis.
From: Potential of GSPT1 as a novel target for glioblastoma therapy
A, B, WT and GSPT1-KO U87 glioblastoma cells were treated with the indicated concentrations (62.5–500 nM) of staurosporine for 9 h. To evaluate apoptosis, WT and GSPT1-KO U87 cell lysates were subjected to immunoblotting using cleaved PARP1 antibody (A). Cleaved fragments of PARP1 were normalized by α-tubulin at each concentration (250, 375, and 500 nM) of staurosporine and plotted (B). n = 5; ****P < 0.0001 by Student t-test; ns non-significant. C–F, Brain tumors transplanted with WT U87 cells or WT U87 cells treated with CC-885 (C, day 24) and WT, GSPT1-KO, or Rescued GSPT1-KO U87 cells (E, day 20) were removed, fixed, and embedded in paraffin. The samples were prepared for immunostaining using cleaved caspase-3 (scale bars: 100 μm). Cleaved caspase-3-positive areas were measured using ImageJ software and plotted. D *P = 0.0142 by Student t-test. n = 4. F *P = 0.0125 (WT vs. GSPT1-KO) and **P = 0.0039 (GSPT1-KO vs. Rescued GSPT1-KO) by one-way ANOVA with Tukey’s post-hoc test. No significant differences were observed between WT and Rescued GSPT1-KO. n = 3.
